Long-term lymphoma risk in thiopurine-treated inflammatory bowel disease: A 15-year propensity-matched cohort study

Table 2 Odds ratio for lymphoma outcomes for patients with inflammatory bowel disease taking thiopurines vs inflammatory bowel disease taking 5-aminosalicylic acid and not taking thiopurines or biologics

Outcomes	Events in IBD with thiopurines	Events in IBD with 5-ASA	OR (95%CI)	P value
Overall lymphoma
1 year	36	26	1.39 (0.84-2.29)	0.1907
3 years	71	30	2.37 (1.54-3.64)	< 0.001
5 years	91	50	1.82 (1.29-2.57)	< 0.001
10 years	136	70	1.95 (1.46-2.60)	< 0.001
15 years	148	77	1.93 (1.46-2.54)	< 0.001
Hodgkin lymphoma
1 year	≤ 10	≤ 10
3 years	≤ 10	≤ 10
5 years	≤ 10	≤ 10
10 years	≤ 10	≤ 10
15 years	26	10	2.60 (1.25-5.40)	0.008
Non-Hodgkin lymphoma
1 year	33	24	1.38 (0.81-2.33)	0.2383
3 years	68	28	2.43 (1.57-3.78)	< 0.001
5 years	85	47	1.81 (1.26-2.58)	0.0009
10 years	125	66	1.90 (1.41-2.56)	< 0.001
15 years	136	70	1.95 (1.46-2.60)	< 0.001
B-cell lymphoma
1 year	33	26	1.27 (0.76-2.13)	0.3153
3 years	63	26	2.43 (1.54-3.83)	< 0.001
5 years	82	49	1.68 (1.17-2.39)	0.0039
10 years	120	65	1.85 (1.36-2.51)	< 0.001
15 years	129	70	1.85 (1.38-2.47)	< 0.001
T-cell/natural killer cell lymphoma
1 year	≤ 10	≤ 10
3 years	≤ 10	≤ 10
5 years	≤ 10	≤ 10
10 years	23	13	1.77 (0.90-3.49)	0.0955
15 years	26	13	2.00 (1.03-3.89)	0.037

Odds ratios of lymphoma outcomes at the 1-year, 3-year, 5-year, 10-year, and 15-year follow-up among propensity score-matched cohorts of patients with inflammatory bowel disease taking thiopurines vs patients with inflammatory bowel disease taking 5-aminosalicylic acid and not taking thiopurines or biologics. Outcomes are presented as event counts with percentage and corresponding odds ratios with 95% confidence intervals. All analyses reflect matched sample sizes of 39618 per group. 5-ASA: 5-aminosalicylates; IBD: Inflammatory bowel disease; OR: Odds ratio; CI: Confidence interval.